Invesco Biotechnology & Genome ETF Rating $93.63 -0.59 (-0.63%) As of 02:03 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock Invesco Biotechnology & Genome ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PBE Aggregate RatingModerate Buy 2.66Holdings in PBE have an aggregate rating of Moderate Buy based on 449 analyst ratings issued in the past year covering 25 companies (89.3% of the portfolio).PBE Aggregate Price Target$93.30-0.35% DownsideHigh Prediction$93.30Average Prediction$93.30Low Prediction$93.30Holdings in PBE have an aggregate price target of $93.30 and a range of $93.30 to $93.30 covering 25 companies (89.3% of the portfolio).PBE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy17 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Invesco Biotechnology & Genome ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 PBE Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.20%REGNRegeneron Pharmaceuticals$805.27-0.1%3.78 of 5 stars2.62$793.74 -1.4%26Insider Trade5.15%AMGNAmgen$414.44-0.8%3.8123 of 5 stars2.35$372.39 -10.1%31Analyst ForecastInsider Trade4.94%VRTXVertex Pharmaceuticals$506.88-1.9%4.4256 of 5 stars2.92$563.50 11.2%244.89%RPRXRoyalty Pharma$58.64+0.1%4.3773 of 5 stars3.00$60.86 3.8%8Analyst Forecast4.81%BIIBBiogen$210.01-0.3%4.0032 of 5 stars2.58$227.07 8.1%33Analyst Downgrade4.38%GILDGilead Sciences$138.19+0.0%4.4525 of 5 stars2.83$158.04 14.4%29Trending NewsAnalyst DowngradeOptions VolumeAnalyst Revision4.31%CDNACareDx$45.34-4.3%3.5269 of 5 stars2.43$47.75 5.3%74.06%UTHRUnited Therapeutics$499.45-0.4%4.355 of 5 stars2.85$646.00 29.3%13Insider TradeAnalyst Revision3.66%TECHBio-Techne$72.33+0.2%3.196 of 5 stars2.06$68.92 -4.7%17Earnings ReportDividend AnnouncementAnalyst Downgrade3.44%ILMNIllumina$191.40-0.6%3.235 of 5 stars2.47$188.40 -1.6%17Positive News3.38%PTGXProtagonist Therapeutics$154.00+1.7%1.6457 of 5 stars2.94$137.86 -10.5%18Analyst UpgradeInsider Trade3.32%VCELVericel$44.26-0.6%4.306 of 5 stars2.57$58.40 32.0%7Positive News3.29%VCYTVeracyte$41.68-2.2%4.4681 of 5 stars2.82$54.33 30.4%11Positive NewsAnalyst Upgrade3.11%ALNYAlnylam Pharmaceuticals$228.04+0.4%4.8293 of 5 stars2.92$393.86 72.7%24Analyst Forecast3.09%INCYIncyte$120.14-0.3%3.5373 of 5 stars2.43$120.65 0.4%23Analyst Forecast3.04%ACADACADIA Pharmaceuticals$28.30-0.3%4.555 of 5 stars2.82$33.69 19.1%17Analyst Forecast3.04%RGENRepligen$167.33-0.1%3.1294 of 5 stars2.94$166.43 -0.5%18Positive News2.95%HALOHalozyme Therapeutics$98.71-1.9%3.8753 of 5 stars2.62$91.20 -7.6%13Insider Trade2.90%NBIXNeurocrine Biosciences$152.32+1.0%4.9877 of 5 stars2.88$200.86 31.9%24Analyst Downgrade2.84%QGENQiagen$42.83-0.9%3.5568 of 5 stars2.36$43.93 2.6%14Options Volume2.79%BMRNBioMarin Pharmaceutical$67.54-1.4%4.8586 of 5 stars2.70$88.00 30.3%23Analyst Downgrade2.73%EXELExelixis$51.10+1.0%3.1006 of 5 stars2.32$49.79 -2.6%19Analyst UpgradeInsider Trade2.72%PTCTPTC Therapeutics$71.75-0.3%3.66 of 5 stars2.64$98.55 37.3%14Analyst Forecast2.66%BCRXBioCryst Pharmaceuticals$9.66-1.6%2.3391 of 5 stars2.67$20.60 113.4%12News CoverageAnalyst Revision2.60%COLLCollegium Pharmaceutical$27.88-1.0%2.9468 of 5 stars2.71$52.60 88.7%7News CoverageAnalyst Downgrade This page (NYSEARCA:PBE) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredWhy I'm sending this one to my own familyBehind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...Behind the Markets | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
